ClinicalTrials.gg
RecruitingNCT05646758Updated Mar 18, 2024

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects

A Phase 1 interventional study of TQB2934 injection in Multiple Myeloma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
76th of 406
140 · median 40
Started
2023
with 59 others
Phase 1
151 of 448
73 open now
Primary completion
2024-10
later than 25 of 274 live
Registered
219th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 76th largest by planned enrollment of the 406 interventional ones that give a count, is one of 60 that started in 2023, is one of 151 in phase 1, reaches primary completion later than 25 of the 274 other live ones, and was the 219th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen) double-specific antibody,and the isoform is IgG1 (Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.TQB2934 for injection is planned for the treatment of patients with multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects volunteered to join the study and signed form (ICF)with good compliance;
  • Age: ≥ 18 years old (when signing ICF); PS score: 0-1; The expected survival period is more than 3 months;
  • Multiple myeloma with diagnostic records and meeting the IMWG diagnostic criteria;
  • In the presence of , at least one of the following criteria must be met:

    1. Serum monoclonal immunoglobulin (M protein)≥1.0g/dL,or urine M protein≥200mg/24h;
    2. Light chain type: serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL, and the ratio of free light chain serum immunoglobulin κ and λ is abnormal;
  • multiple myeloma who have received at least 1 in the past, and are refractory to at least 1 proteasome inhibitor (PI), 1 immunomodulator (IMiD) and 1 CD38 monoclonal antibody;
  • Disease progression during or within 12 months after the last treatment (meeting the PD criteria of IMWG), including refractory or no remission of the last treatment (≥1 cycle) or disease progression within 6 months;
  • Major organ function is good;
  • Female subjects of childbearing age should agree to use measures (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; serum pregnancy/urine pregnancy test within 7 days before study enrollment;

Exclusion criteria

Exclusion Criteria:

  • Comorbidities and medical history:

    1. Other malignant tumors have occurred or are currently suffering from other malignant tumors within 3 years before the first medication.
    2. Unresolved toxic reactions higher than CTC AE grade 1 or higher due to any previous treatment, excluding alopecia, fatigue and peripheral neuropathy;
    3. Major surgical intervention, open , or significant traumatic injury within 28 days prior to first dose;
    4. long-term unhealed wounds or fractures;
    5. Hyperactive/venous thrombosis events occurred within 6 months before the first medication, such as cerebrovascular accidents (including , cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.;
    6. Those who have a history of psychotropic drug abuse and cannot quit or have mental disorders;
    7. Subjects with any severe and/or uncontrolled disease,include:

      1. Unsatisfactory blood pressure control (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg, at least 2 measurements at intervals of more than 24 hours);
      2. Myocardial infarction, unstable angina, CTC AE ≥ grade 2 stable angina, ≥ grade 2 heart failure ( (NYHA) classification), ≥ grade 2 arrhythmia occurred within 6 months before the first medication;
      3. Cardiac ultrasound evaluation: (LVEF) \<50%;
      4. Active or uncontrolled severe bacterial, viral or systemic fungal infection within 28 days before the first dose (≥CTC AE grade 2 infection);
      5. Hepatitis (meeting one of the following criteria: : HBV DNA detection value exceeds the value; : HCV RNA detection value exceeds the upper limit of normal value) or decompensated cirrhosis ( grade B, C grade;
      6. (COPD) and (FEV1) \<60% of predicted value.
      7. Has developed or currently suffered from asthma within 2 years before the first medication;
      8. A history of immunodeficiency, including positive or other acquired, congenital immunodeficiency diseases, or a history of solid organ transplantation (except corneal transplantation), and active or patients who need to receive systemic therapy;
      9. Poorly controlled diabetes (fasting blood glucose (FBG) >10mmol/L);
      10. Suffering from epilepsy and needing treatment;
  • Tumor-related symptoms and treatment:

    1. Diagnosed with amyloidosis, plasma cell leukemia (PCL, peripheral plasma cell ratio ≥ 20%, or absolute plasma cell count ≥ 2×109/L), Waldenstrom macroglobulinemia (WM) or POEMS syndrome;
    2. Known multiple myeloma meningeal or central nervous system invasion or highly suspected meningeal or central nervous system invasion but cannot be identified;
    3. Previously received BCMA-targeted therapy;
    4. Previously received hematopoietic stem cell transplantation or chimeric antigen receptor T (CAR-T), CAR-NK cell therapy; or received autologous hematopoietic stem cell transplantation (ASCT) within 12 weeks before the first drug;
    5. Received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication; received proteasome inhibitor therapy or radiotherapy within 2 weeks before the first medication; received immunomodulator therapy within 1 week before the first medication.(Prophylaxis to prevent infusion-related reactions prior to study drug administration)(Calculate the from the end of the last treatment);
  • research treatment related:

    1. History of vaccination within 28 days before the first dose or planned live attenuated live vaccine vaccination during the study;
    2. Unexplained severe allergy history, known allergy to monoclonal antibody drugs or exogenous human immunoglobulin, or known allergy to TQB2934 for injection or in pharmaceutical preparations;
  • Those who have participated in other anti-tumor drug clinical trials within 4 weeks before the first drug use or have not exceeded 5 drug half-lives;
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered unsuitable for enrollment for other reasons;
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    TQB2934 injection

    intravenous injection. 0.09mg, 0.36 mg, 1mg, 2mg, 3mg, 5mg, 6mg, 10mg, 12mg, 16mg, 20mg each time. once a week in Cycle 1-3. once every 2 weeks in Cycle 4-6. if reach PR and above remission after 6 cycles of administration, once every 4 weeks,28 days as a treatment cycle.

    Drug: TQB2934 injection

Interventions

  • TQB2934 is an anti-CD3×BCMA double-specific antibody,which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    DLT refers to any of the toxicity events in the first administration of TQB2934 for injection to the end of the first treatment cycle.

    Time frame: Up to 18 months

  2. Maximum Tolerated Dose (MTD)

    After the trial, ordinal regression was used to determine the maximum tolerated dose (MTD)

    Time frame: Up to 18 months

  3. Incidence and severity of serious adverse events (AEs)

    Incidence and severity of serios adverse events (AEs) will be reported for safety evaluation.

    Time frame: Up to 18 months

  4. Incidence and severity of adverse events (AEs)

    Incidence and severity of adverse events (AEs) will be reported for safety evaluation.

    Time frame: Up to 18 months

  5. Incidence and severity abnormal laboratory test value

    Incidence and severity abnormal laboratory test value will be reported for safety evaluation.

    Time frame: Up to 18 months

Secondary outcomes

  1. Elimination half-life (t1/2)

    t1/2 is time it takes for the blood concentration of TQB2934 to drop by half.

    Time frame: 120 hours after administration

  2. Area under the plasma concentration-time curve (AUC0-last)

    To characterize the pharmacokinetics of TQB2934 by assessment of area under the plasma concentration time curve.

    Time frame: 120 hours after administration

  3. Apparent clearance (CL)

    Apparent clearance (CL) after administration

    Time frame: 120 hours after administration

  4. Terminal phase apparent volume of distribution (Vz)

    Terminal phase apparent volume of distribution (Vz)

    Time frame: 120 hours after administration

  5. Plasma trough concentration (Cmin)

    Cmin is the minimum plasma concentration of TQB2934.

    Time frame: 120 hours after administration

  6. Overall response rate (ORR)

    Proportion of subjects with best response as PR(Partial relief), VGPR(Very good partial relief), CR(Complete Response), sCR(Strict Complete Response)

    Time frame: Up to 18 months

  7. Clinical benefit rate (CBR)

    Proportion of subjects with best response as MR(Minor relief), PR(Partial relief), VGPR(Very good partial relief), CR(Complete Response), sCR(Strict Complete Response)

    Time frame: Up to 18 months

  8. Very good partial response rate (VGPR)

    Proportion of subjects whose best response is VGPR, CR, sCR;

    Time frame: Up to 18 months

  9. Complete Response (CR) / Strict Complete Response (sCR) Rate

    Proportion of subjects whose best response is CR and sCR;

    Time frame: Up to 18 months

  10. Negative rate of minimal residual disease (MRD)

    The proportion of subjects with negative MRD (\<10-5, multicolor flow cytometry or next-generation sequencing) at any time point from the first administration of the trial drug to disease progression or before receiving new anti-tumor therapy;

    Time frame: Up to 18 months

  11. Duration of remission (DOR)

    For all subjects whose best response was PR, VGPR, CR, sCR, the time from the date of first achieving PR, VGPR, CR, sCR to the date of first definite disease progression or (any cause) death(whichever occurs first).

    Time frame: Up to 18 months

  12. Time to first remission (TTR)

    Among all the subjects whose best response is PR, VGPR, CR, sCR, the time from the first administration of the test drug to the date of the first PR and above remission.

    Time frame: Up to 18 months

  13. Progression-free survival (PFS)

    The time between the first dose of the trial drug and the date of first definite disease progression or death (from any cause), whichever occurs first.

    Time frame: Up to 18 months

  14. Overall survival (OS)

    Time from first dose of study drug to date of death from any cause.

    Time frame: Up to 18 months

  15. Disease status was determined using the International Myeloma Working Group (IMWG) 2016 criteria

    Disease status was determined using the International Myeloma Working Group (IMWG) 2016 criteria

    Time frame: Up to 18 months

  16. Antidrug antibody (ADA) incidence

    Positive incidence of anti-drug antibodies

    Time frame: Up to 18 months

  17. Peripheral blood soluble BCMA (sBCMA) level

    The level of soluble BCMA (sBCMA) in peripheral blood is the pharmacodynamic index of TQB2934.

    Time frame: Up to 18 months

  18. Receptor occupancy rate (RO)

    The receptor occupation (RO) of TQB2934 on immune cells in human body

    Time frame: Up to 18 months

  19. Cytokine Interleukin 2 (IL-2) levels

    The level of cytokine interleukin 2 (IL-2) is the pharmacodynamic index of TQB2934.

    Time frame: Up to 18 months

  20. Cytokine Interleukin 6 (IL-6) levels

    The level of cytokine interleukin 6 (IL-6) is the pharmacodynamic index of TQB2934.

    Time frame: Up to 18 months

  21. Cytokine Interleukin 10 (IL-10) levels

    The level of cytokine interleukin 10 (IL-10) is the pharmacodynamic index of TQB2934.

    Time frame: Up to 18 months

  22. Cytokine Interferon γ (IFN-γ) levels

    The level of cytokine Interferon γ (IFN-γ) is the pharmacodynamic index of TQB2934.

    Time frame: Up to 18 months

  23. Cytokine Interferon α (IFN-α) levels

    The level of cytokine Interferon α (IFN-α) is the pharmacodynamic index of TQB2934.

    Time frame: Up to 18 months

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Oct 2024, 19 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 19 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 12, 2022
StartActual
Mar 17, 2023
Primary completionEst.
Oct 2024
CompletionEst.
Oct 2025
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05646758
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
Mar 17, 2023
Primary completion
Oct 2024 (estimated)
Completion
Oct 2025 (estimated)
Last update
Mar 18, 2024

Study contacts

Peng Liu, Doctor
Contact
Liu.peng@zs-hospital.sh.cn
021-60267405

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934

Start the discussion